NYSEAMERICAN:TOVX Theriva Biologics (TOVX) Stock Price, News & Analysis $0.34 -0.01 (-3.67%) Closing price 05/11/2026 04:10 PM EasternExtended Trading$0.34 0.00 (-1.17%) As of 08:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipSEC FilingsShort InterestBuy This Stock About Theriva Biologics Stock (NYSEAMERICAN:TOVX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Theriva Biologics alerts:Sign Up Key Stats Today's Range$0.33▼$0.3450-Day Range$0.18▼$0.4152-Week Range$0.16▼$0.86Volume2.83 million shsAverage Volume45.26 million shsMarket Capitalization$11.51 millionP/E RatioN/ADividend YieldN/APrice Target$1.00Consensus RatingBuy Company Overview Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland. Read More Theriva Biologics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreTOVX MarketRank™: Theriva Biologics scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingTheriva Biologics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and no sell ratings.Upside PotentialTheriva Biologics has a consensus price target of $1.00, representing about 193.3% upside from its current price of $0.34.Amount of Analyst CoverageTheriva Biologics has only been the subject of 1 research reports in the past 90 days.Read more about Theriva Biologics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Theriva Biologics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Theriva Biologics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTheriva Biologics has a P/B Ratio of 0.74. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.39% of the float of Theriva Biologics has been sold short.Short Interest Ratio / Days to CoverTheriva Biologics has a short interest ratio ("days to cover") of 0.11, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Theriva Biologics has recently increased by 234.42%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTheriva Biologics does not currently pay a dividend.Dividend GrowthTheriva Biologics does not have a long track record of dividend growth. News and Social Media3.1 / 5News Sentiment0.02 News SentimentTheriva Biologics has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Theriva Biologics this week, compared to 0 articles on an average week.Search Interest26 people have searched for TOVX on MarketBeat in the last 30 days. This is an increase of 420% compared to the previous 30 days.MarketBeat Follows4 people have added Theriva Biologics to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Theriva Biologics insiders have not sold or bought any company stock.Percentage Held by Insiders0.67% of the stock of Theriva Biologics is held by insiders.Percentage Held by Institutions6.17% of the stock of Theriva Biologics is held by institutions.Read more about Theriva Biologics' insider trading history. Receive TOVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Theriva Biologics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TOVX Stock News HeadlinesAlliance Global Partners Sticks to Its Buy Rating for Theriva Biologics (TOVX)May 7, 2026 | theglobeandmail.comTheriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial ResultsMay 5, 2026 | globenewswire.comLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top S&P 500 stock for 12 years running—and today, he's giving away his #1 AI stock pick for 2026, free. This company's sales are up 28% year over year, it holds over 30,000 patents in wireless and video technology, and it just earned an A-rating in his proprietary Stock Grader system that has cost him $9 million to build and maintain.May 12 at 1:00 AM | InvestorPlace (Ad)Theriva Biologics stock surges on AACR cancer trial dataApril 21, 2026 | investing.comTheriva Biologics Highlights Positive VCN-01 Pancreatic Cancer DataApril 20, 2026 | theglobeandmail.comTheriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual ...April 19, 2026 | finance.yahoo.comTherivaâ„¢ Biologics anuncia la próxima presentación de datos adicionales del ensayo clÃnico VIRAGE de Fase 2b del VCN-01 para el cáncer de páncreas metastásico en la Reunión Anual de la AACR de 2026April 18, 2026 | globenewswire.comTheriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual MeetingApril 17, 2026 | globenewswire.comSee More Headlines TOVX Stock Analysis - Frequently Asked Questions How have TOVX shares performed this year? Theriva Biologics' stock was trading at $0.2104 at the beginning of 2026. Since then, TOVX stock has increased by 62.1% and is now trading at $0.3410. How were Theriva Biologics' earnings last quarter? Theriva Biologics, Inc. (NYSEAMERICAN:TOVX) released its earnings results on Tuesday, May, 5th. The company reported ($0.05) EPS for the quarter. When did Theriva Biologics' stock split? Theriva Biologics's stock reverse split before market open on Monday, August 26th 2024.The 1-25 reverse split was announced on Friday, August 16th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, August 23rd 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Theriva Biologics? Shares of TOVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Theriva Biologics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Theriva Biologics investors own include BIOLASE (BIOL), Jiuzi (JZXN), Dare Bioscience (DARE), Dermata Therapeutics (DRMA), Faraday Future Intelligent Electric (FFIE), Adial Pharmaceuticals (ADIL) and Aditxt (ADTX). Company Calendar Last Earnings5/05/2026Today5/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (3w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 3 weeks, TOVX's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNYSEAMERICAN:TOVX CIK894158 Webtherivabio.com Phone(301) 417-4364Fax301-417-4367Employees20Year FoundedN/APrice Target and Rating Average Price Target for Theriva Biologics$1.00 High Price Target$1.00 Low Price Target$1.00 Potential Upside/Downside+193.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($33.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$23.74 million Net MarginsN/A Pretax Margin-7,153.00% Return on Equity-178.29% Return on Assets-59.96% Debt Debt-to-Equity Ratio0.11 Current Ratio1.63 Quick Ratio1.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.46 per share Price / Book0.74Miscellaneous Outstanding Shares33,740,000Free Float33,514,000Market Cap$11.51 million OptionableNot Optionable Beta1.17 7 Stocks to Buy And Hold ForeverClick the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (NYSEAMERICAN:TOVX) was last updated on 5/12/2026 by MarketBeat.com Staff. From Our PartnersRead this or regret it foreverThree Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | SponsoredBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceedin...Weiss Ratings | SponsoredGold Is About to Do Something It Hasn’t in 90 YearsThe U.S. Treasury still carries America's gold reserves at $42 per ounce — a price set generations ago. Buried...US Gold Bureau | SponsoredYour book attachedVeteran trader Bill Poulos is giving away his 'Simple Options Trading For Beginners' book - normally $29.97 - ...Profits Run | SponsoredI was right about SpaceXJeff Brown predicted Bitcoin before it climbed as high as 52,400%, Tesla before 2,150%, and Nvidia before 32,0...Brownstone Research | Sponsored"Computers are about to become obsolete" - George Gilder. Here’s why.George Gilder predicted the iPhone 16 years early, called Netflix a decade before it dominated streaming, and ...Eagle Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Theriva Biologics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Theriva Biologics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TOVX Stock Alerts